116 related articles for article (PubMed ID: 10472779)
1. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group.
Kloke O; Klaassen U; Oberhoff C; Hartwich G; Szanto J; Wolf E; Heckmann M; Huhn R; Stephan L; Schnepper U; Donsbach GM; Bechtel C; Rudolph R; Berke A; Borquez D; Hawig I; Hirche H; Schindler AE; Seeber S; Becher R
Breast Cancer Res Treat; 1999 May; 55(1):51-9. PubMed ID: 10472779
[TBL] [Abstract][Full Text] [Related]
2. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
3. Sequential alternating medroxyprogesterone acetate and epirubicin in the treatment of advanced breast cancer.
Smith JA; Green MD; Russell IS; Collins JP
Aust N Z J Surg; 1989 Nov; 59(11):869-72. PubMed ID: 2530970
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
Ghavamzadeh A
Cancer Chemother Pharmacol; 1990; 26 Suppl():S66-8. PubMed ID: 2347052
[TBL] [Abstract][Full Text] [Related]
5. Progestin as an alternative treatment option for multi-treated recurrent triple-negative breast cancer.
Xiangying M; Shikai W; Zefei J; Bing S; Yan M; Xin Z; Lijuan D; Yue W; Tao W; Shaohua Z; Santai S
Swiss Med Wkly; 2013; 143():w13765. PubMed ID: 23740185
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate.
Zaucha R; Sosińska-Mielcarek K; Jassem J
Breast; 2004 Aug; 13(4):321-4. PubMed ID: 15325667
[TBL] [Abstract][Full Text] [Related]
7. Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment.
Toyama T; Yamashita H; Hara Y; Hikosaka Y; Kobayashi S; Iwase H
Int J Clin Oncol; 2001 Dec; 6(6):306-9. PubMed ID: 11828951
[TBL] [Abstract][Full Text] [Related]
8. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
Beltrán M; Alonso MC; Ojeda MB; Izquierdo A; Ferrer J; Picó C; Anglada L; Catalán G; Batiste-Alentorn E; Tusquets I
Ann Oncol; 1991 Jul; 2(7):495-9. PubMed ID: 1832944
[TBL] [Abstract][Full Text] [Related]
9. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer.
Haas R; Schmid H; Hahn U; Hohaus S; Goldschmidt H; Murea S; Kaufmann M; Wannenmacher M; Wallwiener D; Bastert G; Hunstein W
Eur J Cancer; 1997 Mar; 33(3):372-8. PubMed ID: 9155519
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
[TBL] [Abstract][Full Text] [Related]
12. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
Langley RE; Carmichael J; Jones AL; Cameron DA; Qian W; Uscinska B; Howell A; Parmar M
J Clin Oncol; 2005 Nov; 23(33):8322-30. PubMed ID: 16293863
[TBL] [Abstract][Full Text] [Related]
14. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial.
Focan C; Beauduin M; Salamon E; de Greve J; de Wasch G; Lobelle JP; Majois F; Tagnon A; Tytgat J; van Belle S; Vandervellen R; Vindevoghel A;
Br J Cancer; 2001 Jul; 85(1):1-8. PubMed ID: 11437394
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
Joensuu H; Holli K; Heikkinen M; Suonio E; Aro AR; Hietanen P; Huovinen R
J Clin Oncol; 1998 Dec; 16(12):3720-30. PubMed ID: 9850014
[TBL] [Abstract][Full Text] [Related]
18. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
[TBL] [Abstract][Full Text] [Related]
19. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
[TBL] [Abstract][Full Text] [Related]
20. Intensive short-term chemotherapy in patients with advanced breast cancer.
Wander HE; Nagel GA; Luig H; Emrich D
Klin Wochenschr; 1987 Apr; 65(7):317-23. PubMed ID: 2953934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
